News FDA backs Curium's Bexlutry as 1st 'radioligand equivalent' Curium's copycat version of Novartis GEP-NET therapy Lutathera, Bexlutry, is the first radioligand equivalent (RLE) to be approved by the FDA.
News Curium strikes $8bn deal to buy radiopharma rival Lantheus Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.
News Novo says Wegovy shot works in childhood obesity Novo has published the results of a trial of its Wegovy injection in children aged six to 12 with obesity, showing the drug reduced their BMI.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.